CN102803477B - 新城疫病毒的新克隆、其制备及其在癌症医学治疗中的应用 - Google Patents

新城疫病毒的新克隆、其制备及其在癌症医学治疗中的应用 Download PDF

Info

Publication number
CN102803477B
CN102803477B CN201080054157.2A CN201080054157A CN102803477B CN 102803477 B CN102803477 B CN 102803477B CN 201080054157 A CN201080054157 A CN 201080054157A CN 102803477 B CN102803477 B CN 102803477B
Authority
CN
China
Prior art keywords
cancer
mth
virus
treatment
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080054157.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102803477A (zh
Inventor
C.M.查塔里
L.K.查塔里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Cancer Research Institute
Original Assignee
United Cancer Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Cancer Research Institute filed Critical United Cancer Research Institute
Publication of CN102803477A publication Critical patent/CN102803477A/zh
Application granted granted Critical
Publication of CN102803477B publication Critical patent/CN102803477B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
CN201080054157.2A 2009-11-30 2010-08-13 新城疫病毒的新克隆、其制备及其在癌症医学治疗中的应用 Expired - Fee Related CN102803477B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28315409P 2009-11-30 2009-11-30
EP09075536A EP2327764B1 (en) 2009-11-30 2009-11-30 New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
US61/283154 2009-11-30
EP09075536.4 2009-11-30
PCT/IB2010/002227 WO2011064630A1 (en) 2009-11-30 2010-08-13 New clone of newcastle disease virus, its manufacture and its application in the medical treatment of cancer

Publications (2)

Publication Number Publication Date
CN102803477A CN102803477A (zh) 2012-11-28
CN102803477B true CN102803477B (zh) 2014-12-10

Family

ID=41581942

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080054157.2A Expired - Fee Related CN102803477B (zh) 2009-11-30 2010-08-13 新城疫病毒的新克隆、其制备及其在癌症医学治疗中的应用

Country Status (11)

Country Link
US (2) US8377450B2 (enExample)
EP (2) EP2327764B1 (enExample)
JP (1) JP5807788B2 (enExample)
KR (1) KR20120106741A (enExample)
CN (1) CN102803477B (enExample)
AT (1) ATE539148T1 (enExample)
CA (1) CA2782189C (enExample)
DK (1) DK2327764T3 (enExample)
ES (1) ES2380289T3 (enExample)
IL (1) IL207623A (enExample)
WO (1) WO2011064630A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2327764B1 (en) * 2009-11-30 2011-12-28 United Cancer Research Institute New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
KR101636683B1 (ko) * 2013-08-28 2016-07-07 주식회사 바이오포아 내열성이 향상된 뉴캣슬병 바이러스 ｂｐ ａｃｎｄｍ
KR101653401B1 (ko) * 2013-08-28 2016-09-12 주식회사 바이오포아 내열성이 향상된 뉴캣슬병 바이러스 ｂｐ ａｃｎｄ
WO2016073972A1 (en) * 2014-11-07 2016-05-12 Case Western Reserve University Cancer immunotherapy using virus particles
RU2644676C1 (ru) * 2016-10-18 2018-02-13 Общество с ограниченной ответственностью "Витагор" (ООО "ВИТАГОР") Штамм вируса болезни Ньюкасла NDVH-2 для изучения возможности разработки на его основе вирусного онколитического препарата
KR101964610B1 (ko) * 2017-03-13 2019-04-03 대한민국 신규한 종양용해성 바이러스 및 이의 용도
EP3552608A1 (en) * 2018-04-09 2019-10-16 Rapo Yerape B.H. Ltd Increased activity of oncoloytic newcastle disease virus
WO2020043835A1 (en) * 2018-08-31 2020-03-05 Thaller, Arno Novel recombinant newcastle disease virus
CN113913553B (zh) * 2021-10-15 2024-08-27 广西壮族自治区兽医研究所 基因ⅻ型新城疫病毒荧光定量rt-pcr检测试剂盒及其引物对

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU197846B (en) 1984-07-02 1989-06-28 Laszlo Csatary Process for producing therapeutic composition suitable for treating virus infections
HU197517B (en) 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection
DE3806565A1 (de) * 1988-03-01 1989-09-14 Deutsches Krebsforsch Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
US5124148A (en) * 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5215745A (en) * 1988-04-27 1993-06-01 United Cancer Research Institute Method for treating viral diseases with attenuated virus
HU203983B (en) 1988-12-05 1991-11-28 Mta Allatorvostudomanyi Kutato Process for producing living vaccine against fowlpox
ES2188593T3 (es) 1992-03-24 2003-07-01 United Cancer Res Inst Vacuna que contiene un virus vivo.
US5602023A (en) * 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
FR2701580B1 (fr) 1993-02-10 1995-03-24 Bull Sa Procédé d'administration d'applications avec des protocoles standards.
ES2310580T3 (es) 1993-04-30 2009-01-16 Wellstat Biologics Corporation Composiciones purificadas del virus de la enfermedad de newcastle.
JPH08116976A (ja) 1994-10-20 1996-05-14 Chemo Sero Therapeut Res Inst 免疫用核酸調製物およびこれを用いた免疫方法
EP0770397B1 (en) 1995-10-18 2004-04-21 Akzo Nobel N.V. Newcastle disease virus combination vaccine
FR2750866B1 (fr) 1996-06-27 1998-11-27 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
EP1905304A3 (en) 1997-10-09 2008-08-13 Wellstat Biologics Corporation Treatment of neoplasms with viruses
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
CN1477964A (zh) 1999-04-15 2004-02-25 应用病毒治疗肿瘤
AU4971500A (en) 1999-05-05 2000-11-21 University Of Maryland Production of novel newcastle disease virus strains from cdnas and improved liveattenuated newcastle disease vaccines
AU4606000A (en) 1999-06-10 2001-01-02 Agricultural Research Council Vaccine for newcastle disease virus
WO2002000233A2 (en) 2000-06-26 2002-01-03 Wellstat Biologics Corporation Purging of cells using viruses
AU2001270164A1 (en) 2000-06-26 2002-01-08 The United States Of America As Represented By The Secretary Of Agriculture Production of vaccines using transgenic plants
WO2002036617A2 (en) 2000-11-02 2002-05-10 Akzo Nobel N.V. A recombinant newcastle disease virus nucleoprotein mutant as a marker vaccine
IL145397A0 (en) 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
WO2005113013A2 (en) 2004-05-20 2005-12-01 Theravir Management L.P. Compositions of ndv and methods of use thereof for treatment of cancer
US20050220818A1 (en) 2002-06-21 2005-10-06 Wellstat Biologics Corporation Administration of therapeutic viruses
ES2388537T3 (es) * 2002-08-23 2012-10-16 Merck Sharp & Dohme Corp. Inhalador dosificador que contiene una formulación en suspensión de aerosol
AU2003287472A1 (en) 2002-11-05 2004-06-03 Wellstat Biologics Corporation Treating carcinoid neoplasms with therapeuthic viruses
EP1605763A4 (en) 2003-03-24 2008-07-30 Wellstat Biologics Corp ADMINISTRATION OF NEWCASTLE DISEASE VIRUS
CA2519337A1 (en) 2003-03-24 2005-03-03 Wellstat Biologics Corporation Anti-cancer virus desensitization method
WO2005051330A2 (en) 2003-11-25 2005-06-09 United Cancer Research Institute METHOD FOR TREATING HUMAN TUMOR CELLS WITH A NEWCASTLE DISEASE VIRUS STRAIN HAVING A p53 INDEPENDENT ONCOLYTIC EFFECT
WO2005051433A1 (en) 2003-11-25 2005-06-09 United Cancer Research Institute Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent
US20070207149A1 (en) 2004-04-27 2007-09-06 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
KR20070085314A (ko) 2004-11-12 2007-08-27 바이엘 쉐링 파마 악티엔게젤샤프트 재조합 뉴캐슬 질환 바이러스
CA2612949C (en) 2005-07-14 2015-04-28 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
CN1772886A (zh) 2005-09-02 2006-05-17 中国农业科学院哈尔滨兽医研究所 表达传染性法氏囊病毒VP2基因的重组新城疫LaSota弱毒疫苗株
JP5603012B2 (ja) 2005-12-02 2014-10-08 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用
KR100801180B1 (ko) 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
EP2091972B1 (en) 2006-11-27 2016-01-13 Schirrmacher, Dr., Volker Multi-modal cancer therapy using viral hitch-hiking
WO2008140621A2 (en) * 2006-12-21 2008-11-20 Mount Sinai School Of Medicine Of New York University Transgenic oncolytic viruses and uses thereof
CN101205544B (zh) * 2007-08-07 2010-12-08 中国人民解放军第四军医大学 肿瘤靶向性重组新城疫病毒及其构建方法
EP2327764B1 (en) * 2009-11-30 2011-12-28 United Cancer Research Institute New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer

Also Published As

Publication number Publication date
KR20120106741A (ko) 2012-09-26
DK2327764T3 (da) 2012-04-02
JP5807788B2 (ja) 2015-11-10
CN102803477A (zh) 2012-11-28
IL207623A (en) 2014-04-30
CA2782189C (en) 2018-07-10
CA2782189A1 (en) 2011-06-03
IL207623A0 (en) 2011-03-31
WO2011064630A8 (en) 2012-05-24
ES2380289T3 (es) 2012-05-10
HK1175495A1 (en) 2013-07-05
WO2011064630A1 (en) 2011-06-03
US8377450B2 (en) 2013-02-19
EP2507366A1 (en) 2012-10-10
EP2327764B1 (en) 2011-12-28
US20110129446A1 (en) 2011-06-02
EP2327764A1 (en) 2011-06-01
US20140030229A1 (en) 2014-01-30
ATE539148T1 (de) 2012-01-15
JP2013511975A (ja) 2013-04-11

Similar Documents

Publication Publication Date Title
CN102803477A (zh) 新城疫病毒的新克隆、其制备及其在癌症医学治疗中的应用
EP1032269B1 (en) Treatment of neoplasms with interferon-sensitive, clonal viruses
US7736640B2 (en) Methods of treating and detecting cancer using viruses
CN101514334B (zh) 鸡传染性支气管炎病毒弱毒疫苗株及其应用
EP3747997A1 (en) Pseudorabies virus for treating tumors
WO2019015601A1 (zh) 一种用于治疗肿瘤的病毒
EP3783100A1 (en) Coxsackie virus b for treating tumors
JP5897700B2 (ja) 腫瘍崩壊におけるトリメタニューモウイルス
CN109419818A (zh) 一种用于治疗肿瘤的埃可病毒
HK1175495B (en) New clone of newcastle disease virus, its manufacture and its application in the medical treatment of cancer
WO2019174610A1 (zh) 一种溶瘤病毒、合成dna序列及其应用
AU2005237176B2 (en) Treatment of neoplasms with viruses
Kriek IOUOnivIers~ ityIF~ ree~ St~ ate~~~~~~~~~ 34300002088221 Universiteit Vrystaat The Oncolytic Properties of Two Newcastle Disease Virus Strains.
Kriek The oncolytic properties of two newcastle disease virus strains
WO2022000167A1 (zh) 转铁蛋白、转铁蛋白受体及其抗体在制备抗SARS-CoV-2病毒的药物中的应用
Addisu Demeke et al. Current advancements on the significance of oncolytic viruses in the treatment of tumor cells.
Pizzuto Avian influenza virus as an oncolytic therapy for pancreatic cancer
HK1028935B (en) Treatment of neoplasms with interferon-sensitive, clonal viruses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1175495

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1175495

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141210